Nrf2 in Type 2 diabetes and diabetic complications: Yin and Yang

Current Opinion in Toxicology

Volumn 1, Issue , 2016, Pages 9-19

  Fu, Jingqi ^a   Hou, Yongyong ^a   Xue, Peng ^b   Wang, Huihui ^a   Xu, Yuanyuan ^a   Qu, Weidong ^b   Zhang, Qiang ^c   Pi, Jingbo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c EMORY UNIVERSITY   (United States)

Author keywords

Diabetes; Diabetic complications; Insulin resistance; Nrf2; ROS

Indexed keywords

ADVANCED GLYCATION END PRODUCT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ATHEROSCLEROSIS; CARDIOMYOPATHY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; EXERCISE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; WHITE ADIPOSE TISSUE; WOUND HEALING;

EID: 85016769288     PISSN: None     EISSN: 24682020     Source Type: Journal    
DOI: 10.1016/j.cotox.2016.08.001     Document Type: Review

References (162)

1. Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:3 (2011), 311–321.
2. 2 Beagley, J., Guariguata, L., Weil, C., Motala, A.A., Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 103:2 (2014), 150–160.
3. 3 Robertson, R.P., Harmon, J.S., Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:2 (2006), 177–184.
4. Lowell, B.B., Shulman, G.I., Mitochondrial dysfunction and type 2 diabetes. Science 307:5708 (2005), 384–387.
5. 5 Prentki, M., Nolan, C.J., Islet beta cell failure in type 2 diabetes. J Clin Invest 116:7 (2006), 1802–1812.
6. 6 Kajimoto, Y., Kaneto, H., Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 1011 (2004), 168–176.
7. Adams, T.D., Arterburn, D.E., Nathan, D.M., Eckel, R.H., Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 39:6 (2016), 912–923.
8. 8 Laakso, M., Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:5 (1999), 937–942.
9. Russell, N.D., Cooper, M.E., 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. Diabetologia 58:8 (2015), 1708–1714.
10. Forbes, J.M., Cooper, M.E., Mechanisms of diabetic complications. Physiol Rev 93:1 (2013), 137–188.
11. 11 Robertson, R.P., Oxidative stress and impaired insulin secretion in type 2 diabetes. Curr Opin Pharmacol, 2006.
12. 12 Robertson, R.P., Antioxidant drugs for treating beta-cell oxidative stress in type 2 diabetes: glucose-centric versus insulin-centric therapy. Discov Med 9:45 (2010), 132–137.
13. Evans, J.L., Goldfine, I.D., Maddux, B.A., Grodsky, G.M., Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 52:1 (2003), 1–8.
14. Scott, J.A., King, G.L., Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 1031 (2004), 204–213.
15. Houstis, N., Rosen, E.D., Lander, E.S., Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:7086 (2006), 944–948.
16. 16 Robertson, R.P., Harmon, J., Tran, P.O., Poitout, V., Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53:Suppl 1 (2004), S119–S124.
17. 17 Rhee, S.G., Cell signaling. H2O2, a necessary evil for cell signaling. Science 312:5782 (2006), 1882–1883.
18. Watson, J.D., Type 2 diabetes as a redox disease. Lancet 383:9919 (2014), 841–843.
19. 19 Naviaux, R.K., Oxidative shielding or oxidative stress?. J Pharmacol Exp Ther 342:3 (2012), 608–618.
20. Kobayashi, M., Yamamoto, M., Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46 (2006), 113–140.
21. 21 Maher, J., Yamamoto, M., The rise of antioxidant signaling–the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol 244:1 (2011), 4–15.
22. 22 Wiernsperger, N.F., Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab 29:6 (2003), 579–585.
23. 23 Suksomboon, N., Poolsup, N., Sinprasert, S., Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: systematic review of randomized controlled trials. J Clin Pharm Ther 36:1 (2011), 53–63.
24. 24 Suksomboon, N., Poolsup, N., Juanak, N., Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. J Clin Pharm Ther 40:4 (2015), 413–418.
25. Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297:8 (2007), 842–857.
26. 26 Finkel, T., Oxygen radicals and signaling. Curr Opin Cell Biol 10:2 (1998), 248–253.
27. Pi, J., Bai, Y., Zhang, Q., Wong, V., Floering, L.M., Daniel, K., et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 56:7 (2007), 1783–1791.
28. Pi, J., Zhang, Q., Fu, J., Woods, C.G., Hou, Y., Corkey, B.E., et al. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol 244:1 (2010), 77–83.
29. 29 Finkel, T., Oxidant signals and oxidative stress. Curr Opin Cell Biol 15:2 (2003), 247–254.
30. 30 Buetler, T.M., Krauskopf, A., Ruegg, U.T., Role of superoxide as a signaling molecule. News Physiol Sci 19 (2004), 120–123.
31. 31 Dennery, P.A., Effects of oxidative stress on embryonic development. Birth Defects Res C Embryo Today 81:3 (2007), 155–162.
32. 32 Armann, B., Hanson, M.S., Hatch, E., Steffen, A., Fernandez, L.A., Quantification of basal and stimulated ROS levels as predictors of islet potency and function. Am J Transplant 7:1 (2007), 38–47.
33. Goldstein, B.J., Mahadev, K., Wu, X., Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54:2 (2005), 311–321.
34. 34 Leloup, C., Magnan, C., Benani, A., Bonnet, E., Alquier, T., Offer, G., et al. Mitochondrial reactive oxygen species are required for hypothalamic glucose sensing. Diabetes 55:7 (2006), 2084–2090.
35. 35 Fu, J., Woods, C.G., Yehuda-Shnaidman, E., Zhang, Q., Wong, V., Collins, S., et al. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect 118:6 (2010), 864–870.
36. Wang, X., Wu, H., Chen, H., Liu, R., Liu, J., Zhang, T., et al. Does insulin bolster antioxidant defenses via the extracellular signal-regulated kinases-protein kinase B-nuclear factor erythroid 2 p45-related factor 2 pathway?. Antioxid Redox Signal 16:10 (2012), 1061–1070.
37. Pi, J., Zhang, Q., Andersen, M.E., ROS and antioxidants in pancreatic β-cell function: Yin and Yang. Laher, I., (eds.) Systems biology of free radicals and anti-oxidants, 2014, Springer-Verlag Berlin Heidelberg, 10.1007/978-3-642-30018-9_159.
38. Yagishita, Y., Fukutomi, T., Sugawara, A., Kawamura, H., Takahashi, T., Pi, J., et al. Nrf2 protects pancreatic beta-cells from oxidative and nitrosative stress in diabetic model mice. Diabetes 63:2 (2014), 605–618.
39. Uruno, A., Furusawa, Y., Yagishita, Y., Fukutomi, T., Muramatsu, H., Negishi, T., et al. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol Cell Biol 33:15 (2013), 2996–3010.
40. 40 Fu, J., Zheng, H., Wang, H., Yang, B., Zhao, R., Lu, C., et al. Protective role of nuclear factor E2-related factor 2 against acute oxidative stress-induced pancreatic beta-cell damage. Oxid Med Cell Longev, 2015, 2015, 639191.
41. 41 Rosen, E.D., MacDougald, O.A., Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:12 (2006), 885–896.
42. 42 Iozzo, P., Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care 32:Suppl 2 (2009), S168–S173.
43. 43 DeFronzo, R.A., Tripathy, D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32:Suppl 2 (2009), S157–S163.
44. 44 Bugianesi, E., McCullough, A.J., Marchesini, G., Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:5 (2005), 987–1000.
45. 45 Das, U.N., Repossi, G., Dain, A., Eynard, A.R., Is insulin resistance a disorder of the brain?. Front Biosci 16 (2011), 1–12.
46. 46 Nardai, G., Stadler, K., Papp, E., Korcsmaros, T., Jakus, J., Csermely, P., Diabetic changes in the redox status of the microsomal protein folding machinery. Biochem Biophys Res Commun 334:3 (2005), 787–795.
47. 47 Costa, A., Iguala, I., Bedini, J., Quinto, L., Conget, I., Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. Metabolism 51:3 (2002), 372–375.
48. 48 Jimenez-Osorio, A.S., Picazo, A., Gonzalez-Reyes, S., Barrera-Oviedo, D., Rodriguez-Arellano, M.E., Pedraza-Chaverri, J., Nrf2 and redox status in prediabetic and diabetic patients. Int J Mol Sci 15:11 (2014), 20290–20305.
49. 49 McClung, J.P., Roneker, C.A., Mu, W., Lisk, D.J., Langlais, P., Liu, F., et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A 101:24 (2004), 8852–8857.
50. 50 Mehran, A.E., Templeman, N.M., Brigidi, G.S., Lim, G.E., Chu, K.Y., Hu, X., et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16:6 (2012), 723–737.
51. Corkey, B.E., Banting lecture 2011: hyperinsulinemia: cause or consequence?. Diabetes 61:1 (2012), 4–13.
52. 52 Buettner, C., Is hyperinsulinemia required to develop overeating-induced obesity?. Cell Metab 16:6 (2012), 691–692.
53. 53 Ristow, M., Zarse, K., Oberbach, A., Kloting, N., Birringer, M., Kiehntopf, M., et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A 106:21 (2009), 8665–8670.
54. 54 Gomez-Cabrera, M.C., Ristow, M., Vina, J., Antioxidant supplements in exercise: worse than useless?. Am J Physiol Endocrinol Metab 302:4 (2012), E476–E477 author reply E478–9.
55. 55 Petersen, A.C., McKenna, M.J., Medved, I., Murphy, K.T., Brown, M.J., Della Gatta, P., et al. Infusion with the antioxidant N-acetylcysteine attenuates early adaptive responses to exercise in human skeletal muscle. Acta Physiol (Oxf) 204:3 (2012), 382–392.
56. 56 Gliemann, L., Schmidt, J.F., Olesen, J., Bienso, R.S., Peronard, S.L., Grandjean, S.U., et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol 591:20 (2013), 5047–5059.
57. 57 Xue, P., Hou, Y., Zhang, Q., Woods, C.G., Yarborough, K., Liu, H., et al. Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: Involvement of the adaptive antioxidant response. Biochem Biophys Res Commun 407:2 (2011), 360–365.
58. 58 More, V.R., Xu, J., Shimpi, P.C., Belgrave, C., Luyendyk, J.P., Yamamoto, M., et al. Keap1 knockdown increases markers of metabolic syndrome after long-term high fat diet feeding. Free Radic Biol Med 61 (2013), 85–94.
59. Xu, J., Kulkarni, S.R., Donepudi, A.C., More, V.R., Slitt, A.L., Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 61:12 (2012), 3208–3218.
60. Chartoumpekis, D.V., Ziros, P.G., Psyrogiannis, A.I., Papavassiliou, A.G., Kyriazopoulou, V.E., Sykiotis, G.P., et al. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes 60:10 (2011), 2465–2473.
61. Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., Liu, D., et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J Biol Chem 285:12 (2010), 9292–9300.
62. 62 Barroso, E., Rodriguez-Rodriguez, R., Chacon, M.R., Maymo-Masip, E., Ferrer, L., Salvado, L., et al. PPARbeta/delta ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochim Biophys Acta 1852:5 (2015), 1049–1058.
63. 63 Holmstrom, K.M., Baird, L., Zhang, Y., Hargreaves, I., Chalasani, A., Land, J.M., et al. Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open 2:8 (2013), 761–770.
64. 64 Heiss, E.H., Schachner, D., Zimmermann, K., Dirsch, V.M., Glucose availability is a decisive factor for Nrf2-mediated gene expression. Redox Biol 1 (2013), 359–365.
65. 65 Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:4 (2014), 199–218.
66. 66 Furusawa, Y., Uruno, A., Yagishita, Y., Higashi, C., Yamamoto, M., Nrf2 induces fibroblast growth factor 21 in diabetic mice. Genes Cells 19:12 (2014), 864–878.
67. 67 Tanaka, Y., Aleksunes, L.M., Yeager, R.L., Gyamfi, M.A., Esterly, N., Guo, G.L., et al. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 325:2 (2008), 655–664.
68. 68 Hou, Y., Xue, P., Bai, Y., Liu, D., Woods, C.G., Yarborough, K., et al. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein β during adipogenesis. Free Radic Biol Med 52 (2012), 462–472.
69. Xue, P., Hou, Y., Chen, Y., Yang, B., Fu, J., Zheng, H., et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 62:3 (2013), 845–854.
70. Xu, J., Donepudi, A.C., More, V.R., Kulkarni, S.R., Li, L., Guo, L., et al. Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice. Obesity (Silver Spring) 23:2 (2015), 335–344.
71. 71 Slocum, S.L., Skoko, J.J., Wakabayashi, N., Aja, S., Yamamoto, M., Kensler, T.W., et al. Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys 591 (2016), 57–65.
72. 72 Shin, S., Wakabayashi, J., Yates, M.S., Wakabayashi, N., Dolan, P.M., Aja, S., et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide. Eur J Pharmacol, 2009.
73. 73 Saha, P.K., Reddy, V.T., Konopleva, M., Andreeff, M., Chan, L., The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 285:52 (2010), 40581–40592.
74. 74 Yu, Z., Shao, W., Chiang, Y., Foltz, W., Zhang, Z., Ling, W., et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 54:4 (2011), 922–934.
75. 75 Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., Foltz, W., et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One, 7(1), 2012, e28784.
76. Uruno, A., Yagishita, Y., Yamamoto, M., The Keap1-Nrf2 system and diabetes mellitus. Arch Biochem Biophys 566 (2015), 76–84.
77. 77 Chartoumpekis, D.V., Kensler, T.W., New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr Diabetes Rev 9:2 (2013), 137–145.
78. 78 Yates, M.S., Tran, Q.T., Dolan, P.M., Osburn, W.O., Shin, S., McCulloch, C.C., et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30:6 (2009), 1024–1031.
79. 79 Xu, J., Donepudi, A.C., Moscovitz, J.E., Slitt, A.L., Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissue. PLoS One, 8(11), 2013, e79841.
80. 80 Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107:9 (2010), 1058–1070.
81. 81 Maritim, A.C., Sanders, R.A., Watkins, J.B. 3rd, Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17:1 (2003), 24–38.
82. 82 Rydstrom, J., Mitochondrial transhydrogenase–a key enzyme in insulin secretion and, potentially, diabetes. Trends Biochem Sci 31:7 (2006), 355–358.
83. 83 Tan, S.M., de Haan, J.B., Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?. Redox Rep 19:3 (2014), 107–117.
84. 84 Xu, L., Badr, M.Z., Enhanced potential for oxidative stress in hyperinsulinemic rats: imbalance between hepatic peroxisomal hydrogen peroxide production and decomposition due to hyperinsulinemia. Horm Metab Res 31:4 (1999), 278–282.
85. 85 Kyselova, P., Zourek, M., Rusavy, Z., Trefil, L., Racek, J., Hyperinsulinemia and oxidative stress. Physiol Res 51:6 (2002), 591–595.
86. 86 Jiang, T., Chang, Q., Cai, J., Fan, J., Zhang, X., Xu, G., Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy. Oxid Med Cell Longev, 2016, 2016, 3528274.
87. 87 Negi, G., Kumar, A., Sharma, S.S., Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 50:2 (2011), 124–131.
88. 88 Valdecantos, M.P., Prieto-Hontoria, P.L., Pardo, V., Modol, T., Santamaria, B., et al. Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes. Free Radic Biol Med 84 (2015), 263–278.
89. 89 He, M., Nitti, M., Piras, S., Furfaro, A.L., Traverso, N., Pronzato, M.A., et al. Heme oxygenase-1-derived bilirubin protects endothelial cells against high glucose-induced damage. Free Radic Biol Med 89 (2015), 91–98.
90. 90 Karasu, C., Ozansoy, G., Bozkurt, O., Erdogan, D., Omeroglu, S., Antioxidant and triglyceride-lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Metabolism 46:8 (1997), 872–879.
91. Pergola, P.E., Raskin, P., Toto, R.D., Meyer, C.J., Huff, J.W., Grossman, E.B., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:4 (2011), 327–336.
92. 92 Abdo, S., Zhang, S.L., Chan, J.S., Reactive oxygen species and nuclear factor erythroid 2-related factor 2 activation in diabetic nephropathy: a hidden target. J Diabetes Metab, 6(6), 2015.
93. Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., Zhang, D.D., The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59:4 (2010), 850–860.
94. Zheng, H., Whitman, S.A., Wu, W., Wondrak, G.T., Wong, P.K., Fang, D., et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60:11 (2011), 3055–3066.
95. Xu, Z., Wei, Y., Gong, J., Cho, H., Park, J.K., Sung, E.R., et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia 57:1 (2014), 204–213.
96. Whitman, S.A., Long, M., Wondrak, G.T., Zheng, H., Zhang, D.D., Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy. Exp Cell Res 319:17 (2013), 2673–2683.
97. 97 Ungvari, Z., Bagi, Z., Feher, A., Recchia, F.A., Sonntag, W.E., Pearson, K., et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299:1 (2010), H18–H24.
98. 98 Duan, J., Wei, G., Guo, C., Cui, J., Yan, J., Yin, Y., et al. Aralia taibaiensis protects cardiac myocytes against high glucose-induced oxidative stress and apoptosis. Am J Chin Med 43:6 (2015), 1159–1175.
99. 99 Chin, M.P., Wrolstad, D., Bakris, G.L., Chertow, G.M., de Zeeuw, D., Goldsberry, A., et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 20:12 (2014), 953–958.
100. 100 Pergola, P.E., Krauth, M., Huff, J.W., Ferguson, D.A., Ruiz, S., Meyer, C.J., et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33:5 (2011), 469–476.
101. 101 Wu, H., Kong, L., Tan, Y., Epstein, P.N., Zeng, J., Gu, J., et al. C66 ameliorates diabetic nephropathy in mice by both upregulating NRF2 function via increase in miR-200a and inhibiting miR-21. Diabetologia, 2016.
102. 102 Liu, Y., Wang, Y., Miao, X., Zhou, S., Tan, Y., Liang, G., et al. Inhibition of JNK by compound C66 prevents pathological changes of the aorta in STZ-induced diabetes. J Cell Mol Med 18:6 (2014), 1203–1212.
103. 103 Selcuk, M.Y., Aygen, B., Dogukan, A., Tuzcu, Z., Akdemir, F., Komorowski, J.R., et al. Chromium picolinate and chromium histidinate protects against renal dysfunction by modulation of NF-kappaB pathway in high-fat diet fed and Streptozotocin-induced diabetic rats. Nutr Metab (Lond), 9, 2012, 30.
104. 104 Cordero-Herrera, I., Martin, M.A., Goya, L., Ramos, S., Cocoa flavonoids protect hepatic cells against high-glucose-induced oxidative stress: relevance of MAPKs. Mol Nutr Food Res 59:4 (2015), 597–609.
105. 105 Yang, H., Xu, W., Zhou, Z., Liu, J., Li, X., Chen, L., et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes 123:6 (2015), 360–367.
106. 106 Kim, B.H., Lee, E.S., Choi, R., Nawaboot, J., Lee, M.Y., Lee, E.Y., et al. Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 57:3 (2016), 664–673.
107. 107 Zhang, X., Liang, D., Guo, L., Liang, W., Jiang, Y., Li, H., et al. Curcumin protects renal tubular epithelial cells from high glucose-induced epithelial-to-mesenchymal transition through Nrf2-mediated upregulation of heme oxygenase-1. Mol Med Rep 12:1 (2015), 1347–1355.
108. 108 Appendino, G., Belcaro, G., Cornelli, U., Luzzi, R., Togni, S., Dugall, M., et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med 53:3 Suppl 1 (2011), 43–49.
109. 109 Fratantonio, D., Speciale, A., Ferrari, D., Cristani, M., Saija, A., Cimino, F., Palmitate-induced endothelial dysfunction is attenuated by cyanidin-3-O-glucoside through modulation of Nrf2/Bach1 and NF-kappaB pathways. Toxicol Lett 239:3 (2015), 152–160.
110. 110 Yang, Y., Chen, G., Cheng, X., Teng, Z., Cai, X., Yang, J., et al. Therapeutic potential of digitoflavone on diabetic nephropathy: nuclear factor erythroid 2-related factor 2-dependent anti-oxidant and anti-inflammatory effect. Sci Rep, 5, 2015, 12377.
111. Tan, S.M., Sharma, A., Stefanovic, N., Yuen, D.Y., Karagiannis, T.C., Meyer, C., et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes 63:9 (2014), 3091–3103.
112. 112 Deliyanti, D., Lee, J.Y., Petratos, S., Meyer, C., Ward, K., Wilkinson-Berka, J.L., et al. A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy. Clin Sci (Lond), 2016.
113. Tan, Y., Ichikawa, T., Li, J., Si, Q., Yang, H., Chen, X., et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60:2 (2011), 625–633.
114. 114 Foresti, R., Bucolo, C., Platania, C.M., Drago, F., Dubois-Rande, J.L., Motterlini, R., Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacol Res 99 (2015), 296–307.
115. 115 Ha, C.M., Park, S., Choi, Y.K., Jeong, J.Y., Oh, C.J., Bae, K.H., et al. Activation of Nrf2 by dimethyl fumarate improves vascular calcification. Vascul Pharmacol 63:1 (2014), 29–36.
116. 116 Cheng, Y., Zhang, J., Guo, W., Li, F., Sun, W., Chen, J., et al. Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med 93 (2016), 94–109.
117. 117 Song, Y., Wen, L., Sun, J., Bai, W., Jiao, R., Hu, Y., et al. Cytoprotective mechanism of ferulic acid against high glucose-induced oxidative stress in cardiomyocytes and hepatocytes. Food Nutr Res, 60, 2016, 30323.
118. 118 Choi, S.H., Park, S., Oh, C.J., Leem, J., Park, K.G., Lee, I.K., Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation. Vascul Pharmacol 73 (2015), 11–19.
119. 119 Peake, B.F., Nicholson, C.K., Lambert, J.P., Hood, R.L., Amin, H., Amin, S., et al. Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol 304:9 (2013), H1215–H1224.
120. 120 Zhou, X., An, G., Lu, X., Hydrogen sulfide attenuates the development of diabetic cardiomyopathy. Clin Sci (Lond) 128:5 (2015), 325–335.
121. Zhou, X., Feng, Y., Zhan, Z., Chen, J., Hydrogen sulfide alleviates diabetic nephropathy in a streptozotocin-induced diabetic rat model. J Biol Chem 289:42 (2014), 28827–28834.
122. 122 Liu, J., Wu, J., Sun, A., Sun, Y., Yu, X., Liu, N., et al. Hydrogen sulfide decreases high glucose/palmitate-induced autophagy in endothelial cells by the Nrf2-ROS-AMPK signaling pathway. Cell Biosci, 6, 2016, 33.
123. 123 Zhong, P., Wu, L., Qian, Y., Fang, Q., Liang, D., Wang, J., et al. Blockage of ROS and NF-kappaB-mediated inflammation by a new chalcone L6H9 protects cardiomyocytes from hyperglycemia-induced injuries. Biochim Biophys Acta 1852:7 (2015), 1230–1241.
124. 124 Xing, X., Zhang, C., Shao, M., Tong, Q., Zhang, G., Li, C., et al. Low-dose radiation activates Akt and Nrf2 in the kidney of diabetic mice: a potential mechanism to prevent diabetic nephropathy. Oxid Med Cell Longev, 2012, 2012, 291087.
125. 125 Zhang, F., Lin, X., Yu, L., Li, W., Qian, D., Cheng, P., et al. Low-dose radiation prevents type 1 diabetes-induced cardiomyopathy via activation of AKT mediated anti-apoptotic and anti-oxidant effects. J Cell Mol Med, 2016.
126. 126 Li, M., Li, Q., Zhao, Q., Zhang, J., Lin, J., Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences. Int J Clin Exp Pathol 8:9 (2015), 10112–10120.
127. Hur, K.Y., Kim, S.H., Choi, M.A., Williams, D.R., Lee, Y.H., Kang, S.W., et al. Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis 211:1 (2010), 69–76.
128. 128 Nakai, K., Fujii, H., Kono, K., Goto, S., Kitazawa, R., Kitazawa, S., et al. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am J Hypertens 27:4 (2014), 586–595.
129. 129 Zhang, Z., Chen, J., Zhou, S., Wang, S., Cai, X., Conklin, D.J., et al. Magnolia bioactive constituent 4-O-methylhonokiol prevents the impairment of cardiac insulin signaling and the cardiac pathogenesis in high-fat diet-induced obese mice. Int J Biol Sci 11:8 (2015), 879–891.
130. 130 Luo, Z.F., Qi, W., Feng, B., Mu, J., Zeng, W., Guo, Y.H., et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci 88:11–12 (2011), 512–520.
131. Miao, X., Cui, W., Sun, W., Xin, Y., Wang, B., Tan, Y., et al. Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. Am J Physiol Endocrinol Metab 304:1 (2013), E87–E99.
132. 132 Wang, Y., Sun, W., Du, B., Miao, X., Bai, Y., Xin, Y., et al. Therapeutic effect of MG132 on the aortic oxidative damage and inflammatory response in OVE26 type 1 diabetic mice. Oxid Med Cell Longev, 2013, 2013, 879516.
133. 133 Huang, K., Huang, J., Xie, X., Wang, S., Chen, C., Shen, X., et al. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. Am J Physiol Heart Circ Physiol 304:4 (2013), H567–H578.
134. Arellano-Buendia, A.S., Tostado-Gonzalez, M., Garcia-Arroyo, F.E., Cristobal-Garcia, M., Loredo-Mendoza, M.L., Tapia, E., et al. Anti-inflammatory therapy modulates Nrf2-Keap1 in kidney from rats with diabetes. Oxid Med Cell Longev, 2016, 2016, 4693801.
135. 135 Chen, F., Zhang, N., Ma, X., Huang, T., Shao, Y., Wu, C., et al. Naringin alleviates diabetic kidney disease through inhibiting oxidative stress and inflammatory reaction. PLoS One, 10(11), 2015, e0143868.
136. 136 Wang, X., Liu, R., Zhang, W., Zhang, X., Liao, N., Wang, Z., et al. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Mol Cell Endocrinol 376:1–2 (2013), 70–80.
137. Schuhmacher, S., Oelze, M., Bollmann, F., Kleinert, H., Otto, C., Heeren, T., et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 60:10 (2011), 2608–2616.
138. 138 Huang, K., Chen, C., Hao, J., Huang, J., Wang, S., Liu, P., et al. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-beta1 in rat glomerular messangial cells. Mol Cell Endocrinol 399 (2015), 178–189.
139. 139 Ren, X., Sun, H., Zhang, C., Li, C., Wang, J., Shen, J., et al. Protective function of pyridoxamine on retinal photoreceptor cells via activation of the pErk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice. Mol Med Rep, 2016.
140. 140 Padiya, R., Chowdhury, D., Borkar, R., Srinivas, R., Pal Bhadra, M., Banerjee, S.K., Garlic attenuates cardiac oxidative stress via activation of PI3K/AKT/Nrf2-Keap1 pathway in fructose-fed diabetic rat. PLoS One, 9(5), 2014, e94228.
141. 141 Bagul, P.K., Middela, H., Matapally, S., Padiya, R., Bastia, T., Madhusudana, K., et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 66:3 (2012), 260–268.
142. 142 Jiang, B., Guo, L., Li, B.Y., Zhen, J.H., Song, J., Peng, T., et al. Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione s-transferases Mu in diabetic rats. J Med Food 16:6 (2013), 481–486.
143. 143 Palsamy, P., Subramanian, S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812:7 (2011), 719–731.
144. 144 Bonnefont-Rousselot, D., Resveratrol and cardiovascular diseases. Nutrients, 8(5), 2016.
145. 145 Yang, H., Mao, Y., Tan, B., Luo, S., Zhu, Y., The protective effects of endogenous hydrogen sulfide modulator, S-propargyl-cysteine, on high glucose-induced apoptosis in cardiomyocytes: a novel mechanism mediated by the activation of Nrf2. Eur J Pharmacol 761 (2015), 135–143.
146. 146 Velmurugan, G.V., Sundaresan, N.R., Gupta, M.P., White, C., Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res 100:1 (2013), 143–150.
147. 147 Shang, G., Tang, X., Gao, P., Guo, F., Liu, H., Zhao, Z., et al. Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway. J Nutr Biochem 26:6 (2015), 596–606.
148. Wu, H., Kong, L., Cheng, Y., Zhang, Z., Wang, Y., Luo, M., et al. Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2. Free Radic Biol Med 89 (2015), 431–442.
149. 149 Cui, W., Bai, Y., Miao, X., Luo, P., Chen, Q., Tan, Y., et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev, 2012, 2012, 821936.
150. de Haan, J.B., Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 60:11 (2011), 2683–2684.
151. Long, M., Rojo de la Vega, M., Wen, Q., Bharara, M., Jiang, T., Zhang, R., et al. An essential role of NRF2 in diabetic wound healing. Diabetes 65:3 (2016), 780–793.
152. 152 Wang, Y., Zhang, Z., Sun, W., Tan, Y., Liu, Y., Zheng, Y., et al. Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function. Oxid Med Cell Longev, 2014, 2014, 123963.
153. 153 Miao, X., Bai, Y., Sun, W., Cui, W., Xin, Y., Wang, Y., et al. Sulforaphane prevention of diabetes-induced aortic damage was associated with the up-regulation of Nrf2 and its down-stream antioxidants. Nutr Metab (Lond), 9(1), 2012, 84.
154. 154 Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M.T., Zhang, C., et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 57 (2013), 82–95.
155. 155 Xue, M., Qian, Q., Adaikalakoteswari, A., Rabbani, N., Babaei-Jadidi, R., Thornalley, P.J., Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 57:10 (2008), 2809–2817.
156. 156 Hu, Y., Hou, Z., Liu, D., Yang, X., Tartary buckwheat flavonoids protect hepatic cells against high glucose-induced oxidative stress and insulin resistance via MAPK signaling pathways. Food Funct 7:3 (2016), 1523–1536.
157. 157 Li, H., Zhang, L., Wang, F., Shi, Y., Ren, Y., Liu, Q., et al. Attenuation of glomerular injury in diabetic mice with tert-butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation. Am J Nephrol 33:4 (2011), 289–297.
158. 158 Zhong, Q., Mishra, M., Kowluru, R.A., Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 54:6 (2013), 3941–3948.
159. 159 Dong, D., Reece, E.A., Yang, P., The Nrf2 activator vinylsulfone reduces high glucose-induced neural tube defects by suppressing cellular stress and apoptosis. Reprod Sci, 2016.
160. 160 Li, B., Cui, W., Tan, Y., Luo, P., Chen, Q., Zhang, C., et al. Zinc is essential for the transcription function of Nrf2 in human renal tubule cells in vitro and mouse kidney in vivo under the diabetic condition. J Cell Mol Med 18:5 (2014), 895–906.
161. 161 Miao, X., Wang, Y., Sun, J., Sun, W., Tan, Y., Cai, L., et al. Zinc protects against diabetes-induced pathogenic changes in the aorta: roles of metallothionein and nuclear factor (erythroid-derived 2)-like 2. Cardiovasc Diabetol, 12, 2013, 54.
162. de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G.L., Chin, M., Christ-Schmidt, H., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:26 (2013), 2492–2503.